Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (978)	7/13/1998 10:28:00 AM
From: Merav	Read Replies (1) of 1491

I also contacted the Washington Post and some other papers that covered the NIH marijuana-brain-stroke story but I think it's worth analyzing why that story is receiving coverage now while Pharmos is not. The key to the NIH story lies in the word "news". The Post was able to report something to its readers that was new (A highly regarded scientific journal that day published new findings). When Pharmos first reported it's findings several years ago the story also was picked up by leading journals including Business Week and the front page of the influential Israeli daily Ha'aretz. How to explain then something like the Entremed sensation when the New York Times suddenly gave prominent coverage to news that had been reported several months previous in Nature? Clearly, that was an exception to the rule, a quirky situation where the Times health reporter, Gina Kolata, known to be a hard-nut-to-crack, decided, for whatever reasons, to write about the subject. It would be a big mistake to assume that most companies end up getting coverage in this way. Most coverage tends to be milestone-linked; for Pharmos the next milestone will come with the results of the Phase 2 trials. It's instructive to note what an appetite the media has for marijuana-linked stories; when Pharmos does have something new to say on the subject, it follows that the media interest will be substantial. This is not to say that a journalist or two can't be found to write about the Pharmos story even now (the way the Financial Times did about a month ago) and certainly any efforts in that direction are worthwhile; but it's important to be realistic and be prepared for the reply: get back to us as soon as you have the Phase 2 results.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next